Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.

PloS one - 1 Jan 2024

Slomka Jeremy, Berthou Hugo, Mansuet-Lupo Audrey, Blons Hélène, Fabre Elizabeth, Lerner Ivan, Rance Bastien, Alifano Marco, Chapron Jeanne, Birsen Gary, Gibault Laure, Arrondeau Jennifer, Leroy Karen, Wislez Marie

Abstract excerpt

OBJECTIVE: Recent evidence suggests that elevated levels of PD-L1 expression may be linked to early resistance to TKI and reduced survival in NSCLC with EGFR mutations. This study aimed to characterize the clinical and molecular features of EGFR-mutated lung adenocarcinomas and determine the prognostic significance associated with high PD-L1 expression. MATERIALS AND METHODS: We conducted a retrospective chart...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to B7-H1 Antigen

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 39509381
DOI: 10.1371/journal.pone.0307161
PMCID: PMC11542846

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.PMID 39509381Read ↗

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).Semantic proximity Read ↗

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression.Semantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Various impacts of driver mutations on the PD-L1 expression of NSCLC.Semantic proximity Read ↗

PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.Semantic proximity Read ↗

[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].Semantic proximity Read ↗

EGFR and PDL1: A Match (Not) Made in Heaven-A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.